Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 11473–11481 | Cite as

Genetic variants in the KDR gene is associated with the prognosis of transarterial chemoembolization treated hepatocellular carcinoma

  • You-Bing Zheng
  • Jian-Wen Huang
  • Mei-Xiao Zhan
  • Wei Zhao
  • Bing Liu
  • Xu He
  • Yong Li
  • Bao-Shan Hu
  • Li-Gong Lu
Research Article

Abstract

Kinase insert domain receptor (KDR) is the principal receptor that promotes the proangiogenic action of vascular endothelial growth factor and is involved in the tumorigenesis and progression of many malignancies, including hepatocellular carcinoma (HCC). Single-nucleotide polymorphisms (SNPs) of KDR have been reported to be with the risk and prognosis of several malignancies. Our aim was to determine whether SNPs in KDR gene are associated with clinical outcomes in HCC patients treated with transcatheter arterial chemoembolization. A total of 192 HCC patients were tested for KDR SNPs, and the SNP results were correlated with progression-free survival (PFS) and overall survival (OS). The association of the SNPs with the overall survival (OS) of patients was assessed by Kaplan–Meier method, and then Cox proportional hazards model was used to assess the variables resulted significant at univariate analysis. No significant differences were found in correlation between KDR SNPs and patients’ PFS. Our data showed that genotype AA + TA of rs1870377 and genotype CC + TC of rs2071559 were significantly associated with overall survival of HCC patients (P < 0.001 and P < 0.001, respectively) and remained as significant predictors for OS adjusting for high level of serum AFP (>400 μg/L), existence of portal vein tumor thrombus, and high BCLC stage (HR = 0.61; 95 % CI, 0.36–0.88; P = 0.003 and HR = 0.54; 95 % CI, 0.40–0.94; P = 0.002, respectively). Our results suggest that SNPs rs1870377 and rs2071559 in the KDR gene may serve as independent prognosis biomarkers for unresectable HCC patient, which warranted further validating investigation.

Keywords

KDR Hepatocellular carcinoma Prognosis Single-nucleotide polymorphism 

Notes

Acknowledgments

This study was supported by grants 2011A030400009 from Technology Foundation of Guangdong Province, China, and S2012010010569 from Natural Science Foundation of Guangdong Province, China.

Conflicts of interest

None

References

  1. 1.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRefGoogle Scholar
  2. 2.
    Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res. 2000;462:381–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.PubMedCrossRefGoogle Scholar
  6. 6.
    Shastry BS. SNPs: impact on gene function and phenotype. Methods Mol Biol. 2009;578:3–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.PubMedCrossRefGoogle Scholar
  8. 8.
    Hansen TF, Garm SK, Andersen RF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J. 2011;11:53–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008;14:7554–63.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del PM, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108:1126–32.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Scartozzi M, Faloppi L, Svegliati BG, Loretelli C, Piscaglia F, Iavarone M, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study. Int J Cancer. 2014.Google Scholar
  14. 14.
    Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment Pharmacol Ther. 2011;34:196–204.PubMedCrossRefGoogle Scholar
  15. 15.
    Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, et al. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014;31:843.PubMedCrossRefGoogle Scholar
  16. 16.
    Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Tan CK, Law NM, Ng HS, Machin D. Simple clinical prognostic model for hepatocellular carcinoma in developing countries and its validation. J Clin Oncol. 2003;21:2294–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, et al. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol. 2013;54:199–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;2001:e21.Google Scholar
  21. 21.
    Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol. 2007;50:760–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Estevez-Garcia P, Castano A, Martin AC, Lopez-Rios F, Iglesias J, Munoz-Galvan S, et al. PDGFRalpha/beta and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer. 2012;12:514.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Scartozzi M, Bianconi M, Faloppi L, Loretelli C, Bittoni A, Del PM, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br J Cancer. 2013;108:1126–32.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13:724–33.PubMedCrossRefGoogle Scholar
  25. 25.
    Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, Schwartz L, et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, et al. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011;17:5257–67.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • You-Bing Zheng
    • 1
    • 2
  • Jian-Wen Huang
    • 1
  • Mei-Xiao Zhan
    • 1
  • Wei Zhao
    • 1
    • 2
  • Bing Liu
    • 1
  • Xu He
    • 1
  • Yong Li
    • 1
  • Bao-Shan Hu
    • 1
  • Li-Gong Lu
    • 1
  1. 1.Department of Interventional Radiology, Cancer Center, Guangdong General HospitalGuangdong Academy of Medical SciencesGuangzhouChina
  2. 2.Southern Medical UniversityGuangzhouChina

Personalised recommendations